Genprex, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Genprex, Inc. (GNPX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $10.15 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-11-14
- Genprex, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$1.69M.
- Genprex, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $11.98M.
- Genprex, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$136.77K.
- Genprex, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$212.69K, a 110.12% decline year-over-year.
- Genprex, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$1.44M, a 205.33% decline from fiscal 2016.
- Genprex, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $1.37M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|---|
| 2018-09-30 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $10.29M derived: sum of 2 quarters · filed 2018-11-14 | $10.15M 10-Q · filed 2018-11-14 | $9.94M derived: sum of 4 quarters · filed 2018-11-14 | |
| 2018-06-30 | $11.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $11.84M 10-Q · filed 2018-08-14 | $11.63M derived: sum of 3 quarters · filed 2018-08-14 | $11.53M derived: sum of 4 quarters · filed 2018-11-14 | |
| 2018-03-31 | -$136.77K 10-Q · filed 2018-05-15 | -$349.46K derived: sum of 2 quarters · filed 2018-05-15 | -$443.46K derived: sum of 3 quarters · filed 2018-11-14 | -$905.52K derived: sum of 4 quarters · filed 2018-11-14 | |
| 2017-12-31 | -$212.69K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-17 | -$306.69K derived: sum of 2 quarters · filed 2018-11-14 | -$768.76K derived: sum of 3 quarters · filed 2018-11-14 | -$1.44M 10-K · filed 2018-04-17 | |
| 2017-09-30 | -$94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$556.06K derived: sum of 2 quarters · filed 2018-11-14 | -$1.23M 10-Q · filed 2018-11-14 | -$1.23M 10-Q · filed 2017-12-05 | $874.09K derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | -$462.06K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$1.13M 10-Q · filed 2018-08-14 | $968.08K derived: sum of 3 quarters · filed 2018-08-14 | ||
| 2017-03-31 | -$672.29K 10-Q · filed 2018-05-15 | $1.43M derived: sum of 2 quarters · filed 2018-05-15 | |||
| 2016-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-17 | $1.37M 10-K · filed 2018-04-17 | |||
| 2016-09-30 | -$734.36K 10-Q · filed 2017-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |